Stephens Consulting, LLC Genmab A/S Transaction History
Stephens Consulting, LLC
- $422 Billion
- Q2 2025
A detailed history of Stephens Consulting, LLC transactions in Genmab A/S stock. As of the latest transaction made, Stephens Consulting, LLC holds 79 shares of GMAB stock, worth $1,699. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79Holding current value
$1,699% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GMAB
# of Institutions
245Shares Held
65.3MCall Options Held
729KPut Options Held
398K-
Alliancebernstein L.P. New York, NY14.7MShares$317 Million0.11% of portfolio
-
Orbis Allan Gray LTD Hamilton, D05.71MShares$123 Million0.8% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$109 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.43MShares$95.2 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.88MShares$62 Million0.45% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $14.2B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...